Zelira Therapeutics Ltd is a renowned company that holds strong values and corporate philosophy. Committed to excellence, Zelira strives to deliver innovative and effective therapeutic solutions. Their dedication lies in improving the quality of life for patients through the development of clinically validated cannabis-based medicines. With a focus on research and development, Zelira aims to provide evidence-based treatments to address unmet medical needs. Their core principles revolve around integrity, collaboration, and patient-centricity. By maintaining ethical standards and fostering partnerships, Zelira Therapeutics Ltd empowers patients and healthcare practitioners alike, driving advancements in the field of medicinal cannabis.

Zelira Therapeutics Ltd is primarily present in Australia and the United States.

Zelira Therapeutics Ltd, a renowned biopharmaceutical company, has achieved several significant milestones. The company has successfully developed and commercialized innovative therapeutic solutions for various medical conditions. Zelira Therapeutics has witnessed notable milestones, including the establishment of strategic partnerships with leading research institutions and pharmaceutical companies. Additionally, they have obtained regulatory approvals for their groundbreaking pharmaceutical products, enhancing patient access to cutting-edge treatments. Zelira Therapeutics Ltd has demonstrated consistent dedication to pioneering research, driving innovation, and improving patient outcomes. With their unwavering commitment to scientific excellence, Zelira Therapeutics continues to redefine possibilities in the pharmaceutical industry.

Zelira Therapeutics Ltd is a renowned global therapeutic medicinal cannabis company. Founded in 2016, the company focuses on the development and commercialization of innovative pharmaceutical-grade cannabinoid-based therapies. With a mission to improve patients' quality of life, Zelira Therapeutics conducts extensive research to develop evidence-based medicinal cannabis treatments targeting a range of medical conditions. The company collaborates with leading researchers, clinicians, and health organizations to ensure the highest standards in product development. Zelira Therapeutics aims to bring effective and safe cannabis-based therapies to patients worldwide.

Zelira Therapeutics Ltd faces competition from various players in the market. Some of the main competitors of Zelira Therapeutics Ltd include prominent pharmaceutical companies such as GW Pharmaceuticals, Canopy Growth Corporation, and Aphria Inc. These companies also operate in the medical cannabis industry and offer a range of products and services similar to Zelira Therapeutics Ltd. Competition in the market drives innovation and fosters growth, allowing customers to choose from diverse options. Zelira Therapeutics Ltd continues to engage in strategic initiatives to differentiate itself and stay competitive in this dynamic market.

Zelira Therapeutics Ltd is primarily active in the pharmaceutical and healthcare industries.

The business model of Zelira Therapeutics Ltd revolves around developing and commercializing evidence-based pharmaceutical-grade cannabis products for the treatment of various medical conditions. As a leading global medicinal cannabis company, Zelira Therapeutics focuses on research, development, clinical trials, and partnerships to bring innovative therapeutic solutions to patients. With a patient-centered approach, Zelira Therapeutics aims to improve patients' quality of life by providing safe and effective alternative treatments. Through strategic partnerships and collaborations, the company ensures its products reach a wider market, expanding its global footprint in the rapidly evolving medicinal cannabis industry.

Zelira Therapeutics KGV ir 613,71.

Zelira Therapeutics KUV ir 0,15.

AlleAktien kvalitātes vērtējums Zelira Therapeutics ir 7/10.

gaidāmā Zelira Therapeutics apgrozījums ir 46,54 milj. AUD.

gaidāmā Zelira Therapeutics peļņa ir 11 463,50 AUD.

Zelira Therapeutics Ltd is a global company in the pharmaceutical development and sales of medical marijuana products. The company was founded to enhance the development and sales of therapeutic and medical marijuana products. Zelira Therapeutics aims to serve its customers through innovative, effective, and safe products of exceptional quality and efficiency. The business model of Zelira Therapeutics is focused on being a leader in the medical marijuana industry. The company concentrates on innovative products tailored to the needs of patients and doctors. Zelira Therapeutics possesses extensive knowledge and collaboration with renowned companies to develop the latest and most advanced technologies and products. The company has various divisions that focus on the development of medical marijuana products. One of them is the research and development of products tailored to various therapeutic applications such as the treatment of chronic pain, sleep disorders, and inflammation. Zelira Therapeutics has also developed innovative products targeting patients with epilepsy and autism. Another focus of Zelira Therapeutics is the sale of medical marijuana. The company has partnerships with organizations specialized in the manufacturing and sale of medical marijuana. Zelira Therapeutics strives to serve its customers through effective and safe delivery of marijuana products. The company offers various products, including oral sprays, capsules, and topical creams. A popular product of Zelira Therapeutics is the oral spray, which provides a quick and effective method of administering marijuana. The company has also developed a range of topical creams that can be used for pain relief and inflammation. Capsules provide an excellent way to precisely control dosage. Zelira Therapeutics also has a department for international business activities. Here, the company focuses on collaborations with international partners to distribute its products worldwide. The International Business Development department has enabled the company to sell its products in various countries such as Australia, Germany, and Canada. Zelira Therapeutics also has plans to expand into new markets like the United Kingdom and Spain. Overall, Zelira Therapeutics offers differentiated products based on the needs of patients and therapy methods. The company strives to provide its customers with safe, effective, and high-quality marijuana products. With a strong focus on research and development and unique partnerships, Zelira Therapeutics is well-equipped to continue playing a leading role in the medical marijuana industry.

Zelira Therapeutics izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Zelira Therapeutics vai uzņēmums nedod dividendes.

Zelira Therapeutics ISIN ir AU000000ZLD1.

Zelira Therapeutics WKN ir A2AS5H.

Zelira Therapeutics simbols ir ZLD.AX.

Pēdējo 12 mēnešu laikā Zelira Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Zelira Therapeutics plāno maksāt dividendes 0 AUD apmērā.

Zelira Therapeutics pašreizējā dividendu rentabilitāte ir .

Zelira Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Zelira Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Zelira Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Zelira Therapeutics apmērā 0 AUD, kas tika izmaksāta 2.01.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 2.01.2025..

Pēdējās dividendes izmaksa notika 2.01.2025..

Gadā 2024, Zelira Therapeutics izmaksāja 0 AUD dividendes.

Zelira Therapeutics dividendes tiek izmaksātas AUD.